Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Segal, Ehud ^a   Pan, Huaizhong ^b   Ofek, Paula ^a   Udagawa, Taturo ^c   Kopečková, Pavla ^b   Kopeček, Jindřich ^b   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF UTAH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER ALENDRONIC ACID FUMAGILLOL CHLOROACETYLCARBAMATE CONJUGATE; NORLEUCINE; PROLINE; UNCLASSIFIED DRUG; VASCULOTROPIN; POLYMER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE METASTASIS; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INOCULATION; MALE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; POLYMERIZATION; SCID MOUSE; TUMOR CALCINOSIS; CALCINOSIS; CONFOCAL MICROSCOPY; IMMUNOHISTOCHEMISTRY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

MUS;

CALCINOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYMERS;

EID: 65349125338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005233     Document Type: Article

References (75)

1. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69: 1-18.
2. Kansara M, Thomas DM (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26: 1-18.
3. DuBois S, Demetri G (2007) Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109: 813-819.
4. Quan GM, Choong PF (2006) Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 25: 707-713.
5. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
6. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, et al. (2004) Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10: 88-95.
7. Morishita T, Mii Y, Miyauchi Y, Miura S, Honoki K, et al. (1995) Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn J Clin Oncol 25: 25-31.
8. Quattrocchi CC, Piciucchi S, Sammarra M, Santini D, Vincenzi B, et al. (2007) Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med 112: 1049-1059.
9. Hering F, Rodrigues PR, Lipay M (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29: 228-233.
10. Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21: 303-319.
11. Satchi-Fainaro R (2002) Targeting tumor vasculature: reality or a dream? J Drug Target 10: 529-533.
12. Pan H, Kopeckova P, Wang D, Yang J, Miller S, et al. (2006) Water-soluble HPMA copolymer-prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J Drug Target 14: 425-435.
13. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, et al. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10: 255-261.
14. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, et al. (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7: 251-261.
15. Haag R, Kratz F (2006) Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 45: 1198-1215.
16. Becker CM, Wright RD, Satchi-Fainaro R, Funakoshi T, Folkman J, et al. (2006) A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol 168: 2074-2084.
17. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557.
18. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, et al. (1999) A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5: 1989-1995.
19. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
20. Satchi-Fainaro R, Duncan R, Barnes CM (2006) Polymer Therapeutics for Cancer: Current Status and Future Challenges. In: Satchi-Fainaro R, Duncan R, eds (2006) Polymer Therapeutics II: Polymers as Drugs, Conjugates and Gene Delivery Systems. Berlin, Heidelberg: Springer-Verlag. pp 1-68.
21. Duncan R, Ringsdorf H, Satchi-Fainaro R (2006) Polymer therapeutics- polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target 14: 337-341.
22. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, et al. (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67: 9435-9442.
23. Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, et al. (2008) An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 26: 799-807.
24. Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, et al. (2006) A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 13: 1001-1009.
25. Zhao Y, Zhou Y, O'Boyle KM, Murphy PV (2008) Hybrids of 1-deoxynojirimycin and aryl-1,2,3-triazoles and biological studies related to angiogenesis. Bioorg Med Chem 16: 6333-6337.
26. Tucker LA, Zhang Q, Sheppard GS, Lou P, Jiang F, et al. (2008) Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation. Oncogene 27: 3967-3976.
27. Pan H, Sima M, Kopeckova P, Wu K, Gao S, et al. (2008) Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm 5: 548-558.
28. Marino JP Jr, Fisher PW, Hofmann GA, Kirkpatrick RB, Janson CA, et al. (2007) Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J Med Chem 50: 3777-3785.
29. Satchi-Fainaro R, Mann-Steinberg H (2008) TNP-470: The resurrection of the first synthetic angiogenesis inhibitor. In: Folkman WFaJ, ed (2008) Angiogenesis: An integrative approach from science to medicine. Heidelberg, Germany: Springer-Verlag. pp 387-406.
30. Russell RG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, et al. (1970) Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 2: 899-902.
31. Uludag H (2002) Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 8: 1929-1944.
32. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106.
33. Santini D, Vincenzi B, Tonini G (2007) Zoledronic Acid and angiogenesis. Clin Cancer Res 13: 6850-6851.
34. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, et al. (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676.
35. Berenson JR, Lipton A (1999) Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 50: 237-248.
36. Hillner BE (2000) The role of bisphosphonates in metastatic breast cancer. Semin Radiat Oncol 10: 250-253.
37. Lipton A (2008) Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34 Suppl 1: S25-30.
38. Lipton A, Small E, Saad F, Gleason D, Gordon D, et al. (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2: 45-54.
39. Gittens SA, Bansal G, Zernicke RF, Uludag H (2005) Designing proteins for bone targeting. Adv Drug Deliv Rev 57: 1011-1036.
40. El-Mabhouh AA, Angelov CA, Cavell R, Mercer JR (2006) A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer. Nucl Med Biol 33: 715-722.
41. Bagi CM (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57: 995-1010.
42. Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, et al. (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111: 169-180.
43. Tuomela JM, Valta MP, Vaananen K, Harkonen PL (2008) Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer 8: 81.
44. Molinuevo MS, Bruzzone L, Cortizo AM (2007) Alendronate induces antimigratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur J Pharmacol 562: 28-33.
45. Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, et al. (2005) Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 65: 540-545.
46. Hashimoto K, Morishige K, Sawada K, Tahara M, Shimizu S, et al. (2007) Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354: 478-484.
47. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119 Suppl 2: S150-162.
48. Cheng YY, Huang L, Lee KM, Li K, Kumta SM (2004) Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 42: 410-415.
49. Husmann K, Muff R, Bolander ME, Sarkar G, Born W, et al. (2008) Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis. Mol Carcinog 47: 66-73.
50. Miller K, Satchi-Fainaro R (2008) Polymer Therapeutics: From novel concepts to clinical applications. In: Civjan NR, ed (2008) Wiley Encyclopedia of Chemical Biology John Wiley & Sons, Inc.
51. Segal E, Pan H, Ofek P, Udagawa T, Kopeckova P, et al. (2009) A novel combined targeted anticancer and anti-angiogenic polymer therapeutic. PLoS ONE in press.
52. Sanfilippo NJ, Taneja SS, Chachoua A, Lepor H, Formenti SC (2008) Phase I/ II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 26: 2973-2978.
53. Kuljanin J, Jankovic I, Nedeljkovic J, Prstojevic D, Marinkovic V (2002) Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal 28: 1215-1220.
54. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, et al. (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172-181.
55. Miles AA, Miles EM (1952) Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol 118: 228-257.
56. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
57. Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, et al. (2001) Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 74: 135-146.
58. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
59. Hrubý M, Etrych T, Kučka J, Forsterová M, Ulbrich K (2006) Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue. Journal of Applied Polymer Science 101: 3192-3201.
60. Wang D, Miller S, Sima M, Kopečková P, Kopeček J (2003) Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 14: 853-859.
61. Chuman H (2004) [Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas]. Gan To Kagaku Ryoho 31: 1331-1339.
62. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA (2007) Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8: 513-524.
63. Krinick NL, Sun Y, Joyner D, Spikes JD, Straight RC, et al. (1994) A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J Biomat Sci Polym Ed 5: 303-324.
64. Peterson CM, Lu JM, Sun Y, Peterson CA, Shiah JG, et al. (1996) Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res 56: 3980-3985.
65. Shiah JG, Sun Y, Peterson CM, Straight RC, Kopeček J (2000) Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-mesochlorin e6 and adriamycin conjugates in combination treatments. Clin Cancer Res 6: 1008-1015.
66. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, et al. (2005) Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl 44: 4061-4066.
67. Greco F, Vicent MJ, Gee S, Jones AT, Gee J, et al. (2007) Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release 117: 28-39.
68. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
69. Mourad JJ, des Guetz G, Debbabi H, Levy BI (2007) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol.
70. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
71. Motl S (2005) Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 62: 1021-1032.
72. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, et al. (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol.
73. Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K, et al. (2005) The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 146: 633-641.
74. Dunn D, Dehner LP (1977) Metastatic osteosarcoma to lung: a clinicopathologic study of surgical biopsies and resections. Cancer 40: 3054-3064.
75. Gomez Font R, Martinez Garcia ML, Olmos Martinez JM (2008) Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal 13: E318-324.